Skip to main content
SpringerLink
Log in

Neuromyelitis Optica Spectrum Disorders (NMOSD)

  • Neurologic Ophthalmology and Otology (R Shin and D Gold, Section Editors)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Abstract

Purpose of review

The term neuromyelitis optica spectrum disorders (NMOSD) encompasses a constellation of potentially devastating inflammatory maladies of the central nervous system that predominantly affect the optic nerve(s) and spinal cord. Neurologic disability occurs as a result of severe, immune-mediated demyelination and irreversible axonal damage. Significant advances have been made in defining the clinical characteristics of NMOSD, including key examination findings and specific imaging and laboratory indicators. This review will provide the clinician with critical knowledge to allow for both early diagnosis, and consideration of available treatment strategies.

Recent findings

As attacks of NMOSD tend to be severe and irreversible, relapse prevention is essential to the mitigation of permanent neurologic disability. Newly FDA-approved monoclonal antibodies have become available for the management of NMOSD; these may provide clinical stability and reduction in relapses over time.

Summary

NMOSD frequently causes irreversible neurologic disability, and therefore early diagnosis and appropriate pharmacologic intervention are essential. Several previously established as well as newer medications are available for the treatment of acute attacks and for relapse prevention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Reproduced from: Wingerchuk DM, Banwell B, Bennett JL, Cabre P et al. Neurology 2015;85(2).

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as:

    • Of importance

      •• Of major importance

      1. Devic E. Myélite aiguë compliquée de névrite optique. Bull Med (Paris). 1894;8:1033.

        Google Scholar 

      2. Gault F. De la neuromyélite optique aiguë, Lyon 1894.

      3. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6:805–15. https://doi.org/10.1016/S1474-4422(07)70216-8.

        Article  CAS  PubMed  Google Scholar 

      4. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473–7. https://doi.org/10.1084/jem.20050304.

        Article  CAS  PubMed  PubMed Central  Google Scholar 

      5. Jung JS, Bhat RV, Preston GM, Guggino WB, Barbaran JM, Agre P. Molecular characterization of an aquaporin cDNA from brain: candidate osmoreceptor and regulator of water balance. Proc Natl Acad Sci USA. 1994;91:13052–6. https://doi.org/10.1073/pnas.91.26.13052.

        Article  CAS  PubMed  PubMed Central  Google Scholar 

      6. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106–12. https://doi.org/10.1016/S0140-6736(04)17551-X.

        Article  CAS  PubMed  Google Scholar 

      7. Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 2012;11:535–44. https://doi.org/10.1016/S1474-4422(12)70133-3.

        Article  CAS  PubMed  PubMed Central  Google Scholar 

      8. Flanagan EP, Cabre P, Weinshenker BG, St Sauver J, Jacobson DJ, Majed M, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol. 2016;79(5):775–83. https://doi.org/10.1002/ana.24617.

        Article  CAS  PubMed  PubMed Central  Google Scholar 

      9. Bukhari W, Prain KM, Waters P, Woodhall M, O’Gorman CM, Clarke L, et al. Incidence and prevalence of NMOSD in Australia and New Zealand. J Neurol Neurosurg Psychiatry. 2017;88:632–8. https://doi.org/10.1136/jnnp-2016-314839.

        Article  PubMed  Google Scholar 

      10. Miyamoto K, Fujihara K, Kira JI, Kuriyama N, Matsui M, Tamakoshi A, et al. Nationwide epidemiological study of neuromyelitis optica in Japan. J Neurol Neurosurg Psychiatry. 2018;89:667–8. https://doi.org/10.1136/jnnp-2017-317321.

        Article  PubMed  Google Scholar 

      11. Mori M, Kuwabara S, Paul F. Worldwide prevalence of neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry. 2018;89:555–6. https://doi.org/10.1136/jnnp-2017-317566.

        Article  PubMed  Google Scholar 

      12. Kim SH, Mealy MA, Levy M, Schmidt F, Ruprecht K, Paul F, et al. Racial differences in neuromyelitis optica spectrum disorder. Neurology. 2018;91(22):e2089. https://doi.org/10.1212/WNL.0000000000006574.

        Article  PubMed  PubMed Central  Google Scholar 

      13. Wingerchuk DM. Neuromyelitis optica: effect of gender. J Neurol Sci. 2009;286:18–23. https://doi.org/10.1016/j.jns.2009.08.045.

        Article  CAS  PubMed  Google Scholar 

      14. Matiello M, Kim HJ, Kim W, Brum DG, Barriera AA, Kingsbury DJ, et al. Familial neuromyelitis optica. Neurology. 2010;75:310–5. https://doi.org/10.1212/WNL.0b013e3181ea9f15.

        Article  CAS  PubMed  PubMed Central  Google Scholar 

      15. Ghezzi A, Bergamaschi R, Martinelli V, Trojano M, Tola MR, Merelli E, et al. Clinical characteristics, course and prognosis of relapsing Devic’s Neuromyelitis Optica. J Neurol. 2004;251:47–52. https://doi.org/10.1007/s00415-004-0271-0.

        Article  PubMed  Google Scholar 

      16. Drori T, Chapman J. Diagnosis and classification of neuromyelitis optica (Devic’s syndrome). Autoimmun Rev. 2014;13:531–3. https://doi.org/10.1016/j.autrev.2014.01.034.

        Article  CAS  PubMed  Google Scholar 

      17. Merle H, Olindo S, Bonnan M, Donnino A, Richer R, Smadja D, et al. Natural history of the visual impairment of relapsing neuromyelitis optica. Ophthalmology. 2007;114:810–5. https://doi.org/10.1016/j.ophtha.2006.06.060.

        Article  PubMed  Google Scholar 

      18. Cabre P, González-Quevedo A, Bonnan M, Saiz A, Olindo S, Graus F, et al. Relapsing neuromyelitis optica: long term history and clinical predictors of death. J Neurol Neurosurg Psychiatry. 2009;80:1162–4. https://doi.org/10.1136/jnnp.2007.143529.

        Article  CAS  PubMed  Google Scholar 

      19. •• Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll WM, Chitnis T. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–9. https://doi.org/10.1212/WNL.0000000000001729. An important consensus statement summarizingaccumulated clinical and research findings supporting the diagnosis of NMOSD.This is valuable to the clinician in allowing for early diagnosis.

        Article  PubMed  PubMed Central  Google Scholar 

      20. Sherman E, Han MH. Acute and chronic management of neuromyelitis optica spectrum disorder. Curr Treat Options Neurol. 2015;17:48. https://doi.org/10.1007/s11940-015-0378-x.

        Article  PubMed  PubMed Central  Google Scholar 

      21. • Bonnan M, Valentino R, Debeugny S, Merle H, Ferge JL, Mehdaoui H, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2018;89:346–51. https://doi.org/10.1136/jnnp-2017-316286. Emphasizes the importance of maintaining an early clinical suspicion of NMO in the appropriate clinical setting, and ensuring that early plasma exchange is provided to increase the likelihood of clinical recovery.

        Article  PubMed  Google Scholar 

      22. Weinshenker BG, O’Brien PC, Patterson TM, Noseworthy JH, Lucchinetti CF, Dowdick DW, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999;46(6):878–86.

        Article  CAS  PubMed  Google Scholar 

      23. •• Pittock SJ, Berthele A, Fujihara K, Jin Kim H, Levy M, Palace J, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381:614–25. https://doi.org/10.1056/NEJMoa1900866. A clinical trial summarizing a newly-approved therapy for NMOSD.

        Article  CAS  PubMed  Google Scholar 

      24. •• Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock S, Wingerchuk DM, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019;394:1352–63. https://doi.org/10.1016/S0140-6736(19)31817-3. A clinical trial summarizing a newly-approved therapy for NMOSD.

        Article  CAS  PubMed  Google Scholar 

      25. •• Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381:2114–24. https://doi.org/10.1056/NEJMoa1901747. A clinical trial summarizing a newly-approved therapy for NMOSD.

        Article  CAS  PubMed  Google Scholar 

      26. •• Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19:402. https://doi.org/10.1016/S1474-4422(20)30078-8. A clinical trial summarizing a newly-approved therapy for NMOSD.

        Article  CAS  PubMed  PubMed Central  Google Scholar 

      27. Nikoo Z, Badihian S, Shaygannejad V, Asgari N, Ashtari F. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol. 2017;264:2003–9. https://doi.org/10.1007/s00415-017-8590-0.

        Article  CAS  PubMed  Google Scholar 

      28. Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020;19:298–306. https://doi.org/10.1016/S1474-4422(20)30066-1.

        Article  CAS  PubMed  Google Scholar 

      29. Zhang C, Zhang M, Qiu W, Ma H, Zhang X, Zhu Z, et al. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020;19:391. https://doi.org/10.1016/S1474-4422(20)30070-3.

        Article  CAS  PubMed  PubMed Central  Google Scholar 

      30. Ringelstein M, Ayzenberg I, Harmel J, Lauenstein AS, Lensch E, Stogbauer F, et al. Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol. 2015;72:756–63. https://doi.org/10.1001/jamaneurol.2015.0533.

        Article  PubMed  Google Scholar 

      31. Papeix C, Vidal JS, de Seze J, Pierrot-Deseilligny C, Tourbah A, Stankoff B, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler. 2007;13:256–9. https://doi.org/10.1177/1352458506070732.

        Article  CAS  PubMed  Google Scholar 

      32. Shimizu J, Hatanaka Y, Hasegawa M, Iwata A, Sugimoto I, Date H, et al. IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology. 2010;75:1423–7. https://doi.org/10.1212/WNL.0b013e3181f8832e.

        Article  CAS  PubMed  Google Scholar 

      33. Jacob A, Hutchinson M, Elsone L, Kelly S, Ali R, Saukans R, et al. Does natalizumab therapy worsen neuromyelitis optica? Neurology. 2012;79:1065–6. https://doi.org/10.1212/WNL.0b013e31826845fe.

        Article  PubMed  Google Scholar 

      34. Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler. 2012;18:113–5. https://doi.org/10.1177/1352458511431973.

        Article  CAS  PubMed  Google Scholar 

      35. Nechema Y, Moreh E, Weingarden H, Bloch A, Givon U, Vaknin-Dembinski A, et al. Effectiveness of multi-disciplinary rehabilitation for patients with neuromyelitis optica. J Spinal Cord Med. 2016;39(3):311–6. https://doi.org/10.1179/2045772315Y.0000000060.

        Article  Google Scholar 

      36. Chitnis T, Ness J, Krupp L, Waubant E, Hunt T, Olsen CS, et al. Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report. Neurology. 2016;86:245–52. https://doi.org/10.1212/WNL.0000000000002283.

        Article  PubMed  PubMed Central  Google Scholar 

      37. Fragoso YD, Sousa NAC, Saad T, Alves-Leon SV, Pimentel MLV, Goncalves MVM, et al. Clinical characteristics of patients with neuromyelitis optica spectrum disorders with early onset. J Child Neurol. 2019;34:487–90. https://doi.org/10.1177/0883073819842421.

        Article  PubMed  Google Scholar 

      Download references

      Author information

      Authors and Affiliations

      1. Mercy Health Hauenstein Neurosciences, 245 Cherry Street SE, Suite 204, Grand Rapids, MI, 49503, USA

        Christopher C. Glisson DO, MS, FAAN

      Authors
      1. Christopher C. Glisson DO, MS, FAAN
        View author publications

        You can also search for this author in PubMed Google Scholar

      Corresponding author

      Correspondence to Christopher C. Glisson DO, MS, FAAN.

      Additional information

      Publisher's Note

      Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

      This article is part of the Topical Collection on Neurologic Ophthalmology and Otology

      Rights and permissions

      Reprints and permissions

      About this article

      Check for updates. Verify currency and authenticity via CrossMark

      Cite this article

      Glisson, C.C. Neuromyelitis Optica Spectrum Disorders (NMOSD). Curr Treat Options Neurol 24, 241–251 (2022). https://doi.org/10.1007/s11940-022-00709-4

      Download citation

      • Published:

      • Issue Date:

      • DOI: https://doi.org/10.1007/s11940-022-00709-4

      Keywords

      Search

      Navigation